Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
Categories (click each to see list of all clinical trials associated with that category): Lung/Thoracic
Current Status: Open to accrual
Phase: II (Cancer Control)
Principal Investigator: Ernani, Vinicius
Contact Information:
Shannon Pivovar, RN
402-559-8711
shannon.pivovar@unmc.edu
Eligibility: https://www.clinicaltrials.gov/ct2/show/NCT03285321#eligibility
Summary
This study is an open label, multicenter, randomized phase II trial of consolidation immunotherapy with either nivolumab alone or the combination of nivolumab and ipilimumab following concurrent chemoradiation in patients with unresectable stage III NSCLC.